Table 2

Multivariate adjusted ORs of liver cirrhosis and hepatocellular carcinoma (HCC)‡

Liver cirrhosisHCC
Group II+Group IV vs Group I*Group III+Group IV vs Group I†
Control (n=2789)Case (n=642)OR (95% CI)p ValueControl (n=2789)Case (n=780)OR (95% CI)p Value
rs2296651 (S267F)
 GG2274 (81.5)550 (85.7)1.002274 (81.5)679 (87.1)1.00
 GA/AA515 (18.5)92 (14.3)0.65 (0.49 to 0.86)0.002515 (18.5)101 (13.0)0.54 (0.41 to 0.71)<0.001
Age, mean years (SD)45.1 (9.64)49.7 (9.90)1.07 (1.05 to 1.08)<0.00145.1 (9.64)50.7 (10.2)1.08 (1.07 to 1.09)<0.001
Gender
 Female1125 (40.3)162 (25.2)1.001125 (40.3)237 (30.4)1.00
 Male1664 (59.7)480 (74.8)1.94 (1.56 to 2.42)<0.0011664 (59.7)543 (69.6)1.45 (1.18 to 1.77)<0.001
Serum alanine aminotransferase level, U/L
 <452656 (95.2)455 (70.9)1.002656 (95.2)516 (66.2)1.00
 ≥45133 (4.77)187 (29.1)4.99 (3.80 to 6.59)<0.001133 (4.77)264 (33.9)7.11 (5.47 to 9.23)<0.001
HBV DNA level, copies/mL
 <300769 (27.6)53 (8.26)1.00769 (27.6)53 (6.79)1.00
 300–9999943 (33.8)101 (15.7)1.68 (1.18 to 2.40)0.004943 (33.8)135 (17.3)2.35 (1.66 to 3.34)<0.001
 10 000–99 999498 (17.9)108 (16.8)3.37 (2.35 to 4.84)<0.001498 (17.9)151 (19.4)4.74 (3.33 to 6.73)<0.001
 ≥100 000579 (20.8)380 (59.2)9.27 (6.68 to 12.86)<0.001579 (20.8)441 (56.5)10.9 (7.83 to 15.15)<0.001
  • *Comparison of patients with liver cirrhosis to patients without liver cirrhosis and HCC.

  • †Comparison of patients who developed HCC to patients without liver cirrhosis and HCC.

  • ‡HBsAg titre, HBeAg serostatus and HBV genotype were not included in this analysis due to the unavailability of these data in the Taiwan Liver Cancer Network (TLCN) cohort.